Bank of New York Mellon’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Bank of New York Mellon’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-38,065	Closed	-$1.06M	–	4294
2019 Q3	$1.06M	Sell	38,065 -1,693	-4%	-$27.4K	﹤0.01%	3145
2019 Q2	$560K	Sell	39,758 -6,680	-14%	-$63.5K	﹤0.01%	3544
2019 Q1	$413K	Sell	46,438 -3,469	-7%	-$28.2K	﹤0.01%	3630
2018 Q4	$378K	Buy	49,907 +2,313	+5%	+$37.2K	﹤0.01%	3618
2018 Q3	$998K	Buy	47,594 +1,220	+3%	+$29.1K	﹤0.01%	3257
2018 Q2	$1.39M	Buy	46,374 +30,750	+197%	+$837K	﹤0.01%	3060
2018 Q1	$423K	Buy	15,624 +383	+3%	+$11.5K	﹤0.01%	3655
2017 Q4	$439K	Buy	15,241 +1,243	+9%	+$34.1K	﹤0.01%	3665
2017 Q3	$340K	Buy	+13,998	New	+$332K	﹤0.01%	3718

Bank of New York Mellon's DOVA Position: Q4 2019 in Review

Bank of New York Mellon sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 38,065 shares — an estimated $1.06M sold.

Bank of New York Mellon first reported a position in DOVA in Q3 2017 and held it in 9 quarters. The position peaked at $1.39M in Q2 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

Bank of New York Mellon reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Bank of New York Mellon sold 38,065 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $1.06M.
Bank of New York Mellon first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
Bank of New York Mellon's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.39M in Q2 2018.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Bank of New York Mellon's 13F filing for Q4 2019, filed 14 Feb 2020.